LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and ...
In recent years, artificial intelligence (AI) has made significant strides in transforming various domains, from healthcare to finance. One area that is rapidly gaining attention is business ...
Bolstered by fast processing speeds and cheap memory, simulation has become far more accessible than in the past. Thus, the development tool has transformed product development. Simulation has ...
Constantine Davides, an analyst from JMP Securities, has initiated a new Hold rating on Simulations Plus (SLP). Constantine Davides has given his Hold rating due to a combination of factors including ...
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced ...
Screen: Pro-ficiency creates clinical trial simulations, filling a gap for the Simulations Plus suite of products. So far, 2024 is shaping up to be a banner year for Simulations Plus Inc. The ...
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today hosted its ...
IT strategy is shifting from one-off updates to managing six overlapping waves, like digital workforces and virtual simulations, that all need to work together.
RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results